CN109402082A - A kind of Taq DNA polymerase mutant body and its application - Google Patents
A kind of Taq DNA polymerase mutant body and its application Download PDFInfo
- Publication number
- CN109402082A CN109402082A CN201811414588.XA CN201811414588A CN109402082A CN 109402082 A CN109402082 A CN 109402082A CN 201811414588 A CN201811414588 A CN 201811414588A CN 109402082 A CN109402082 A CN 109402082A
- Authority
- CN
- China
- Prior art keywords
- leu
- ala
- glu
- arg
- dna polymerase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1252—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07007—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
Abstract
The present invention provides a kind of Taq DNA polymerase mutant body and its application, Taq DNA polymerase mutant body of the present invention, it is insertion in the amino acid sequence of the Taq archaeal dna polymerase as shown in SEQ ID NO.1, replaces or lack one or more amino acid, or one or more amino acid are added or deleted in one or two end of SEQ ID NO.1 sequence, and compared with the Taq archaeal dna polymerase shown in the SEQ ID NO.1, sensitivity is expanded and amino acid sequence that yield enhances.Taq DNA polymerase mutant body of the present invention increases relative to former Taq archaeal dna polymerase, sensitivity and yield, can be also used for the multiplex amplification of low quality sample.
Description
Technical field
The present invention relates to field of biotechnology, and in particular to a kind of Taq DNA polymerase mutant body and its application.
Background technique
High throughput sequencing technologies rely on its less expensive price at present, more comprehensively, deeper into ground to full-length genome divide
The advantage of analysis, which has been obtained, to be widely applied, scientific research, medical diagnosis on disease and in terms of have great significance.?
It in many practical applications, does not need that full-length genome is sequenced, and only needs to analyze specific gene group region.Targeting sequencing
Technology is exactly to carry out the high throughput sequencing technologies that specificity builds library sequencing to the specific target site of genome.Targeting sequencing at present can
It is realized by two ways, first is that targeted probes capture sequencing, second is that amplicon is sequenced.Amplicon sequencing is emerging by design sense
The primer of the genome area of interest carries out PCR amplification, is enriched with to target area, carries out for the PCR product of specific length
Library is built, the variation in sequencing analysis sequence is passed through.It is sequenced using amplicon, researcher can be to key interested in genome
Region carries out primary study, and this method can efficiently find, verify and screen the genome mutation of region-of-interest.Relative to complete
For genome or full sequencing of extron group, amplicon sequencing have it is with strong points, data volume is few, flexibility is high, analysis is simple,
It is sequenced that the period is short, sequencing depth is high, many advantages such as at low cost.
Target area enrichment is realized by multiplexed PCR amplification, the basic principle of multiplex PCR (multiplex PCR), anti-
Answer reagent and operation identical as Standard PCR, difference is in multiplex PCR system to expand respectively not containing 2 pairs or multipair primer
Same template, multiple targets are carried out while be detected, thus multiplex PCR is more quick, easy.It is multipair in multiplex PCR system to draw
The presence of object easily causes the generation of the non-specific amplification based on primer dimer, and therefore, when design primer should comprehensively consider
The homology of primer length, G/C content and primer and target sequence.The annealing temperature of each primer should be closer to, so that each primer pair
Its corresponding target sequence has identical amplification efficiency.Since Taq archaeal dna polymerase is Mg2+Enzyme is relied on, dNTP, primer are also dependent on
In Mg2+, so best Mg2+Concentration has a great impact to the specificity of balance amplification and sensitivity, usually dense according to dNTP
Degree, template DNA amount and buffer composition determine Mg2+Concentration.
Current amplicon sequencing is to carry out end reparation after being enriched to target area by PCR amplification and add A, adjunction
Head, purification of samples run glue and recycle purpose band, and PCR amplification runs glue and recycles master tape, send sequencing.Amplicon builds the successful key in library
Place is the enrichment (multiplex PCR) of the target area of the first step, and obtaining the target area that yield is high, uniformity is good just can guarantee
Subsequent smooth building sequencing library.Many researchs all concentrate on optimization multiplex PCR process at present, it is expected that obtaining amplification sensitivity
Multiplex amplification reagent high, specific good and that more different samples can be suitable for.
Existing amplifing reagent less effective in product uniformity and yield, shows the sample for poor quality,
Such as: fixed paraffin embedding (FFPE) sample of formalin, cell free DNA (cfDNA) and sample input amount are lower (low
In 0.1ng) when, the sensitivity of reagent is inadequate, and target area cannot preferably expand.Existing amplifing reagent is different in amplification
When TM value system, compatibility is poor, these defects all have a great impact to the building of subsequent sequencing library.
Summary of the invention
It is an object of the present invention to provide a kind of Taq DNA polymerase mutant bodies.
The second purpose of the present invention is to provide application of the Taq DNA polymerase mutant body in field of biotechnology.
The purpose of the present invention can be realized by following scheme:
A kind of Taq DNA polymerase mutant body is the amino acid of the Taq archaeal dna polymerase as shown in SEQ ID NO.1
It is inserted into sequence, replaces or lack one or more amino acid, or added in one or two end of SEQ ID NO.1 sequence
Add or delete one or more amino acid, and compared with the Taq archaeal dna polymerase shown in the SEQ ID NO.1, amplification sensitivity and
The amino acid sequence that yield enhances.
In an embodiment of the present invention, Taq DNA polymerase mutant body of the present invention, the mutant exist
It is each to replace use with the amino acid substitution on following one or more amino acid positions in sequence shown in SEQ ID NO.1
Triplet indicates: alphabet-numeric playing-letter, wherein the position of digital representation mutating acid, and the corresponding mutation of the letter before number relates to
And amino acid, the letter after number indicates the amino acid for replacing amino acid before number: K53N, G364D, R636H.
In an embodiment of the present invention, Taq DNA polymerase mutant body of the present invention, sequence such as SEQ ID
Shown in NO.2, or the amino acid with Taq DNA polymerase activity with sequence shown in SEQ ID NO.2 with 80% identity
Sequence；It is preferred that having 85% identity, more preferably have 90% identity, most preferably, there is 95% identity.
The present invention also provides the nucleotide sequences for encoding Taq DNA polymerase mutant body of the present invention.
In an embodiment of the present invention, the present invention provides a kind of nucleotide for encoding Taq DNA polymerase mutant body
Sequence, as shown in SEQ ID NO.4.
The present invention also provides a kind of comprising encoding the nucleotide sequence of Taq DNA polymerase mutant body of the present invention
Recombinant vector.
The present invention also provides Taq DNA polymerase mutant body of the present invention or the coding of the present invention present invention
The nucleotide sequence or recombinant vector of the present invention of the Taq DNA polymerase mutant body are in field of biotechnology
Application.It is more specific preferred, it is the application in the field PCR especially in multiplex PCR field.
Taq DNA polymerase mutant body of the present invention or coding Taq DNA of the present invention of the present invention
The application of the nucleotide sequence of polymerase mutant or recombinant vector of the present invention in field of biotechnology, can be by
It is carried out according to the system or process of PCR this field routine or existing in the prior art, such as according to Chinese patent
201610140002.X the process of unitary construction amplification sublibrary in carries out.
In a kind of preferred embodiment of the invention, the application in the field PCR is added in amplification system
Reaction additives, the additive are selected from one or more of glycerol, trehalose, DMSO or gelatin.One kind is used alone to add
Agent is added to be conducive to improve amplification sensitivity, several various additive combined uses can preferably promote amplification sensitivity and compatibility
Property.
It is further preferred that the addition volume of the additive is the 0.5 of the reaction system total volume of each amplified reaction
~15%, it is still more preferably 1~5%, most preferably 1~3%；If it is in 2 × Multi-PCR Mix, then preferably
It is the 1~30% of reaction system total volume, is still more preferably 2~10%, most preferably 2~6%.
In a kind of preferred embodiment of the invention, the application in the field PCR contains in amplification system
The amount of KCl, the KCl are each amplified reaction of 20~60mM, each amplified reaction of preferably 40~60mM, most preferably 50mM
Each amplified reaction；If it is in 2 × Multi-PCR Mix, then preferably 40~120mM, further preferred 80~
120mM, most preferably 100mM.
Amplification system of the present invention, can be on the basis of using additive, further by adjusting in buffer
Salt ion (such as KCl) concentration, preferably optimization reaction.
In a kind of particularly preferred embodiment of the invention, the application in the field PCR, each amplified reaction
It include: 1~3U of Taq-Mut, Tris 20~60mM of 20~30mM, KCl, additive 0.5~15%, MgCl20.5~
0.1~0.3mM of 1.5mM, dNTP, pH7.5~7.7.Wherein Taq-Mut refers to Taq DNA polymerase mutant of the present invention
Body, the content of the KCl is as previously mentioned, each amplified reaction of further preferred 40~60mM, each amplification of most preferably 50mM
Reaction；Additive is selected from one or more of glycerol, trehalose, DMSO or gelatin；The additive is preferably 1~5%, most
Preferably 1~3%.
The present invention also provides the kits comprising Taq DNA polymerase mutant body of the present invention.
The present invention also provides application of the kit in field of biotechnology, especially build answering in library in amplicon
With application such as PCR, in multiplex PCR.
The present invention can be by selecting suitable Taq DNA polymerase mutant body, and it is suitable to be then added in amplification system
Reaction additives, adjust the ion concentration of reaction buffer, by the amplifing reagent and primer digestion, joint connection technology mutually ties
It closes, can obtain being applied to the kit that amplicon builds library, the sensitivity and compatibility of amplification be further increased, relative to original
System, the amplification sublibrary of the system construction have many advantages, such as yield height, and library uniformity is good.
Taq DNA polymerase mutant body of the present invention has relative to former Taq archaeal dna polymerase, sensitivity and yield
It is improved, can be also used for the multiplex amplification of low quality sample.
Relational language is explained
Multiplex PCR (multiplex PCR): also known as Multiplex PCR or composite PCR, it is in same PCR reaction system
In add two pairs or more primers, while amplifying the PCR reaction of multiple nucleic acid fragments, reaction principle, reaction reagent and operation
Process is identical as general PCR.
High throughput sequencing technologies: also known as second generation sequencing technologies, next-generation sequencing technologies can be abbreviated as NGS.Refer to one
The secondary technology for carrying out sequencing to millions of DNA moleculars to hundreds of thousands parallel, measurement sequence length are generally shorter.High pass
Measure sequence mainly include following below scheme: the collection and nucleic acid extraction of sample, target sequence enrichment and sequencing library building, sequencing and
Interpretation of result.
Amplicon library construction: general to be enriched to target area by PCR amplification, end adds A connector, connection after repairing
DNA fragmentation after connector carries out PCR amplification and Quality Control, sequencing and interpretation of result.
Detailed description of the invention
Fig. 1 is Taq-wt and Taq-Mut multiplex amplification nucleic acid electrophoresis figure of the present invention；
Fig. 2 is the multiplex amplification nucleic acid electrophoresis figure that Taq-Mut prepares 3 different systems；
Fig. 3 is amplification 2100 testing result of sublibrary Agilent Bioanalyzer.
Specific embodiment
Below with reference to embodiment, the present invention will be further described, it should be understood that specific embodiment described herein is only
To explain the present invention, it is not intended to limit the present invention, all letters under concept thereof of the invention to preparation method of the present invention
Single improve belongs within protection scope of the present invention.
Experimental method in following embodiments is unless otherwise specified conventional method.Examination as used in the following examples
Material is tested, is to be commercially available from routine biochemistry reagent shop unless otherwise specified.
Embodiment 1
Conventionally using Nanjing Vazyme Biotechnology Co., Ltd. 2 ×Max Master Mix
(P515) andUltra One Step Cloning Kit (C115) is to Taq archaeal dna polymerase (sequence such as SEQ
Shown in ID NO.1) rite-directed mutagenesis is carried out, the primer for point mutation is as follows, obtains mutant, referred to as Taq-Mut, dashes forward
Displacement point is: K53N, G364D, R636H (sequence is as shown in SEQ ID NO.2), the nucleic acid sequence such as SEQ ID before mutation
Shown in NO.3, the nucleic acid sequence after mutation is as shown in SEQ ID NO.4.
Primer sequence used in point mutation (5 ' -3 ') is as follows:
AB-1F:GGTATATCTCCTTCTTAAAGATGAGGGGGATGCTGCCC
AB-1R:TCCTTGAGGGCGTTGAGGAGGCTCTTGGCGAAGC
BC-1F:CTCCTCAACGCCCTCAAGGAG
BC-1R:AGGCCAAGGTCTTCCCTCAGGGCCAGAACG
CD-1F:CTGAGGGAAGACCTTGGCCTC
CD-1R:CGTGTGGATGTCGTGCCCCTCCTGGAAG
DE-1F:AGGGGCACGACATCCACACGGAGACCGCCAGCTGGATGT
DE-1R:GATAACAATTCCCCTCTAGATCCTTGGCGGAGAGCCAGT
EA-1F:TCTAGAGGGGAATTGTTATCCGC
EA-1R:CTTTAAGAAGGAGATATACCATGGGC
Obtained Taq-Mut is used to prepare multiplex amplification system, 293T cellular nucleic acid DNA is extracted by conventional method and makees
For the template of amplification, reaction system (1 ×) is as follows: Taq-Mut 2U, Tris 25mM, KCl 20mM, MgCl21mM, dNTP
0.2mM, primer 10nM each, pH7.6, DNA input amount 1ng, control group wild type Taq (Taq-wt) 2U, other components contain
Measure constant, two repetitions.
Primer is 207 pairs in system, is 207 primers for expanding Human tumor related gene hot spot mutation region
It is right.Response procedures are as follows: 99 DEG C of 2min；(99℃15sec；60℃4min)；22 circulations；72℃10min；4℃hold.3%
Ago-Gel run nucleic acid electrophoresis, obtain result as shown in Figure 1, it is seen that: the product obtained using the multiplex amplification of Taq-Mut
Electrophoretic band is brighter, illustrates that Taq-Mut is higher relative to Taq-wt sensitivity and yield.
Embodiment 2Taq-Mut builds the application in library in amplicon
Different reaction systems, which is formulated as follows, using Taq-Mut carries out PCR:
Multiplex amplification reaction system 1:Taq-Mut 2U, Tris 25mM, KCl 20mM, MgCl21mM, dNTP 0.2mM,
Primer 10nM each, DNA input amount 1ng, pH7.6；
Multiplex amplification reaction system 2:Taq-Mut 2U, Tris 25mM, KCl 20mM, DMSO 2%, MgCl21mM,
DNTP 0.2mM, primer 10nM each, DNA input amount 1ng, pH7.6；
Multiplex amplification reaction system 3:Taq-Mut 2U, Tris 25mM, KCl 50mM, DMSO 2%, MgCl21mM,
DNTP 0.2mM, primer 10nM each, DNA input amount 1ng, pH7.6；
Above-mentioned 3 systems carry out multiplex amplification, 293T cellular nucleic acid DNA, input amount 1ng, and response procedures are as follows: 99 DEG C
2min；(99℃15sec；60℃4min)；22 circulations；72℃10min；4℃hold.3% Ago-Gel runs nov nucleic acid
Swimming obtains as shown in Figure 2 as a result, system 1 is not use additive under low ion concns (KCl 20mM)；System 2 is low ion
Under concentration (KCl 20mM), use additive (DMSO 2%)；System 3 is to use additive under high ion concentration (KCl50mM)
(DMSO 2%).As shown in Figure 2: 3 systems all use Taq-Mut, can be further by using DMSO relative to system 1
Promote amplification, by the combined use of additive and high ion concentration buffer, can further promote to expand.
Embodiment 3
Reagent needed for being formulated for multiplex amplification includes amplifing reagent Multi-PCR Mix, which is
2 × concentration, key component concentration are as follows: Taq-Mut 4U, Tris 50mM, KCl 100mM, DMSO 4%, MgCl22mM, dNTP
0.4mM, pH7.6.In conjunction with Adapters the and Ligation Enzyme Mix that conventional connection needs, with amplification human tumor phase
207 primer pairs (Nanjing Vazyme Biotechnology Co., Ltd., the VAHTS AmpSeq in correlation gene hot spot mutation region
Cancer HotSpot Panel NA102), sample be people FFPE sample and each one, cfDNA sample of people, with conventional side
After formula extracts DNA, reaction system (1 × concentration): Taq-Mut 2U, Tris 25mM, KCl 50mM, MgCl21mM, DMSO
2%, dNTP 0.2mM, primer 10nM each, pH7.6, FFPE DNA input amount 10ng/cfDNA input amount 1ng, primer disappear
Change, jointing, purifying, amplified library, library purifying obtains amplification sublibrary WK1, WK2, with common wild type Taq DNA
It polymerize enzymatic reagent, the buffer of additive and high ion concentration is not used, obtained amplification sublibrary WK3, WK4 passes through Qubit
The concentration in above-mentioned 4 libraries is detected with qPCR, and is surveyed after being detected by AgilentBioanalyzer 2100 in Illumina
Sequence platform carries out high-flux sequence, rear to carry out data analysis, obtains the result as described in table 1, Fig. 3 and table 2.
As known from Table 1: be directed to FFPE sample, the library output (concentration) that system after optimization obtains, by Qubit and
All than obviously increasing before optimization after qPCR detection；For cfDNA sample, also obvious output is higher for the system after optimization.
Table 1: library output information
As can be seen from Figure 3: A schemes (WK1) and B figure (WK3) is the row Agilent Bioanalyzer for FFPE sample
2100 as a result, the peak of the position abscissa 70-80s is purpose peak, and the numerical value that ordinate is shown represents yield, it is known that, after optimization
Library (WK1) yield of system construction is higher than the system being not optimised.C figure (WK2) and D figure (WK4) are for cfDNA sample
Agilent Bioanalyzer 2100 is as a result, the peak of the position abscissa 200-300bp is purpose peak, as can be known from Fig. 3, optimization
System (WK2) afterwards can obtain purpose peak, and the system (WK4) being not optimised can not obtain library substantially.
Uniformity indicates that uniformity, the data are shown in table 2, either FFPE sample or the building of cfDNA sample
Amplification sublibrary, the system uniformity after optimization be significantly higher than optimization before system.
Table 2: machine data evaluation under amplification sublibrary
Sequence table
<110>Nanjing Vazyme Biotechnology Co., Ltd.
<120>a kind of Taq DNA polymerase mutant and its application
<160> 4
<170> SIPOSequenceListing 1.0
<210> 1
<211> 832
<212> PRT
<213>artificial sequence (Artificial Sequence)
<400> 1
Met Arg Gly Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu Leu
1 5 10 15
Val Asp Gly His His Leu Ala Tyr Arg Thr Phe His Ala Leu Lys Gly
20 25 30
Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe Ala
35 40 45
Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Asp Ala Val Ile Val
50 55 60
Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Gly Gly
65 70 75 80
Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln Leu
85 90 95
Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Leu Ala Arg Leu Glu
100 105 110
Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Ser Leu Ala Lys Lys
115 120 125
Ala Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Lys Asp
130 135 140
Leu Tyr Gln Leu Leu Ser Asp Arg Ile His Val Leu His Pro Glu Gly
145 150 155 160
Tyr Leu Ile Thr Pro Ala Trp Leu Trp Glu Lys Tyr Gly Leu Arg Pro
165 170 175
Asp Gln Trp Ala Asp Tyr Arg Ala Leu Thr Gly Asp Glu Ser Asp Asn
180 185 190
Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Arg Lys Leu Leu
195 200 205
Glu Glu Trp Gly Ser Leu Glu Ala Leu Leu Lys Asn Leu Asp Arg Leu
210 215 220
Lys Pro Ala Ile Arg Glu Lys Ile Leu Ala His Met Asp Asp Leu Lys
225 230 235 240
Leu Ser Trp Asp Leu Ala Lys Val Arg Thr Asp Leu Pro Leu Glu Val
245 250 255
Asp Phe Ala Lys Arg Arg Glu Pro Asp Arg Glu Arg Leu Arg Ala Phe
260 265 270
Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu Leu
275 280 285
Glu Ser Pro Lys Ala Leu Glu Glu Ala Pro Trp Pro Pro Pro Glu Gly
290 295 300
Ala Phe Val Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp Ala Asp
305 310 315 320
Leu Leu Ala Leu Ala Ala Ala Arg Gly Gly Arg Val His Arg Ala Pro
325 330 335
Glu Pro Tyr Lys Ala Leu Arg Asp Leu Lys Glu Ala Arg Gly Leu Leu
340 345 350
Ala Lys Asp Leu Ser Val Leu Ala Leu Arg Glu Gly Leu Gly Leu Pro
355 360 365
Pro Gly Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro Ser Asn
370 375 380
Thr Thr Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp Thr Glu
385 390 395 400
Glu Ala Gly Glu Arg Ala Ala Leu Ser Glu Arg Leu Phe Ala Asn Leu
405 410 415
Trp Gly Arg Leu Glu Gly Glu Glu Arg Leu Leu Trp Leu Tyr Arg Glu
420 425 430
Val Glu Arg Pro Leu Ser Ala Val Leu Ala His Met Glu Ala Thr Gly
435 440 445
Val Arg Leu Asp Val Ala Tyr Leu Arg Ala Leu Ser Leu Glu Val Ala
450 455 460
Glu Glu Ile Ala Arg Leu Glu Ala Glu Val Phe Arg Leu Ala Gly His
465 470 475 480
Pro Phe Asn Leu Asn Ser Arg Asp Gln Leu Glu Arg Val Leu Phe Asp
485 490 495
Glu Leu Gly Leu Pro Ala Ile Gly Lys Thr Glu Lys Thr Gly Lys Arg
500 505 510
Ser Thr Ser Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His Pro Ile
515 520 525
Val Glu Lys Ile Leu Gln Tyr Arg Glu Leu Thr Lys Leu Lys Ser Thr
530 535 540
Tyr Ile Asp Pro Leu Pro Asp Leu Ile His Pro Arg Thr Gly Arg Leu
545 550 555 560
His Thr Arg Phe Asn Gln Thr Ala Thr Ala Thr Gly Arg Leu Ser Ser
565 570 575
Ser Asp Pro Asn Leu Gln Asn Ile Pro Val Arg Thr Pro Leu Gly Gln
580 585 590
Arg Ile Arg Arg Ala Phe Ile Ala Glu Glu Gly Trp Leu Leu Val Ala
595 600 605
Leu Asp Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala His Leu Ser Gly
610 615 620
Asp Glu Asn Leu Ile Arg Val Phe Gln Glu Gly Arg Asp Ile His Thr
625 630 635 640
Glu Thr Ala Ser Trp Met Phe Gly Val Pro Arg Glu Ala Val Asp Pro
645 650 655
Leu Met Arg Arg Ala Ala Lys Thr Ile Asn Phe Gly Val Leu Tyr Gly
660 665 670
Met Ser Ala His Arg Leu Ser Gln Glu Leu Ala Ile Pro Tyr Glu Glu
675 680 685
Ala Gln Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys Val Arg
690 695 700
Ala Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Arg Arg Gly Tyr Val
705 710 715 720
Glu Thr Leu Phe Gly Arg Arg Arg Tyr Val Pro Asp Leu Glu Ala Arg
725 730 735
Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met Pro
740 745 750
Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys Leu
755 760 765
Phe Pro Arg Leu Glu Glu Met Gly Ala Arg Met Leu Leu Gln Val His
770 775 780
Asp Glu Leu Val Leu Glu Ala Pro Lys Glu Arg Ala Glu Ala Val Ala
785 790 795 800
Arg Leu Ala Lys Glu Val Met Glu Gly Val Tyr Pro Leu Ala Val Pro
805 810 815
Leu Glu Val Glu Val Gly Ile Gly Glu Asp Trp Leu Ser Ala Lys Glu
820 825 830
<210> 2
<211> 832
<212> PRT
<213>artificial sequence (Artificial Sequence)
<400> 2
Met Arg Gly Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu Leu
1 5 10 15
Val Asp Gly His His Leu Ala Tyr Arg Thr Phe His Ala Leu Lys Gly
20 25 30
Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe Ala
35 40 45
Lys Ser Leu Leu Asn Ala Leu Lys Glu Asp Gly Asp Ala Val Ile Val
50 55 60
Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Gly Gly
65 70 75 80
Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln Leu
85 90 95
Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Leu Ala Arg Leu Glu
100 105 110
Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Ser Leu Ala Lys Lys
115 120 125
Ala Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Lys Asp
130 135 140
Leu Tyr Gln Leu Leu Ser Asp Arg Ile His Val Leu His Pro Glu Gly
145 150 155 160
Tyr Leu Ile Thr Pro Ala Trp Leu Trp Glu Lys Tyr Gly Leu Arg Pro
165 170 175
Asp Gln Trp Ala Asp Tyr Arg Ala Leu Thr Gly Asp Glu Ser Asp Asn
180 185 190
Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Arg Lys Leu Leu
195 200 205
Glu Glu Trp Gly Ser Leu Glu Ala Leu Leu Lys Asn Leu Asp Arg Leu
210 215 220
Lys Pro Ala Ile Arg Glu Lys Ile Leu Ala His Met Asp Asp Leu Lys
225 230 235 240
Leu Ser Trp Asp Leu Ala Lys Val Arg Thr Asp Leu Pro Leu Glu Val
245 250 255
Asp Phe Ala Lys Arg Arg Glu Pro Asp Arg Glu Arg Leu Arg Ala Phe
260 265 270
Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu Leu
275 280 285
Glu Ser Pro Lys Ala Leu Glu Glu Ala Pro Trp Pro Pro Pro Glu Gly
290 295 300
Ala Phe Val Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp Ala Asp
305 310 315 320
Leu Leu Ala Leu Ala Ala Ala Arg Gly Gly Arg Val His Arg Ala Pro
325 330 335
Glu Pro Tyr Lys Ala Leu Arg Asp Leu Lys Glu Ala Arg Gly Leu Leu
340 345 350
Ala Lys Asp Leu Ser Val Leu Ala Leu Arg Glu Asp Leu Gly Leu Pro
355 360 365
Pro Gly Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro Ser Asn
370 375 380
Thr Thr Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp Thr Glu
385 390 395 400
Glu Ala Gly Glu Arg Ala Ala Leu Ser Glu Arg Leu Phe Ala Asn Leu
405 410 415
Trp Gly Arg Leu Glu Gly Glu Glu Arg Leu Leu Trp Leu Tyr Arg Glu
420 425 430
Val Glu Arg Pro Leu Ser Ala Val Leu Ala His Met Glu Ala Thr Gly
435 440 445
Val Arg Leu Asp Val Ala Tyr Leu Arg Ala Leu Ser Leu Glu Val Ala
450 455 460
Glu Glu Ile Ala Arg Leu Glu Ala Glu Val Phe Arg Leu Ala Gly His
465 470 475 480
Pro Phe Asn Leu Asn Ser Arg Asp Gln Leu Glu Arg Val Leu Phe Asp
485 490 495
Glu Leu Gly Leu Pro Ala Ile Gly Lys Thr Glu Lys Thr Gly Lys Arg
500 505 510
Ser Thr Ser Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His Pro Ile
515 520 525
Val Glu Lys Ile Leu Gln Tyr Arg Glu Leu Thr Lys Leu Lys Ser Thr
530 535 540
Tyr Ile Asp Pro Leu Pro Asp Leu Ile His Pro Arg Thr Gly Arg Leu
545 550 555 560
His Thr Arg Phe Asn Gln Thr Ala Thr Ala Thr Gly Arg Leu Ser Ser
565 570 575
Ser Asp Pro Asn Leu Gln Asn Ile Pro Val Arg Thr Pro Leu Gly Gln
580 585 590
Arg Ile Arg Arg Ala Phe Ile Ala Glu Glu Gly Trp Leu Leu Val Ala
595 600 605
Leu Asp Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala His Leu Ser Gly
610 615 620
Asp Glu Asn Leu Ile Arg Val Phe Gln Glu Gly His Asp Ile His Thr
625 630 635 640
Glu Thr Ala Ser Trp Met Phe Gly Val Pro Arg Glu Ala Val Asp Pro
645 650 655
Leu Met Arg Arg Ala Ala Lys Thr Ile Asn Phe Gly Val Leu Tyr Gly
660 665 670
Met Ser Ala His Arg Leu Ser Gln Glu Leu Ala Ile Pro Tyr Glu Glu
675 680 685
Ala Gln Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys Val Arg
690 695 700
Ala Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Arg Arg Gly Tyr Val
705 710 715 720
Glu Thr Leu Phe Gly Arg Arg Arg Tyr Val Pro Asp Leu Glu Ala Arg
725 730 735
Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met Pro
740 745 750
Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys Leu
755 760 765
Phe Pro Arg Leu Glu Glu Met Gly Ala Arg Met Leu Leu Gln Val His
770 775 780
Asp Glu Leu Val Leu Glu Ala Pro Lys Glu Arg Ala Glu Ala Val Ala
785 790 795 800
Arg Leu Ala Lys Glu Val Met Glu Gly Val Tyr Pro Leu Ala Val Pro
805 810 815
Leu Glu Val Glu Val Gly Ile Gly Glu Asp Trp Leu Ser Ala Lys Glu
820 825 830
<210> 3
<211> 2496
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 3
atgaggggga tgctgcccct ctttgagccc aagggccggg tcctcctggt ggacggccac 60
cacctggcct accgcacctt ccacgccctg aagggcctca ccaccagccg gggggagccg 120
gtgcaggcgg tctacggctt cgccaagagc ctcctcaagg ccctcaagga ggacggggac 180
gcggtgatcg tggtctttga cgccaaggcc ccctccttcc gccacgaggc ctacgggggg 240
tacaaggcgg gccgggcccc cacgccggag gactttcccc ggcaactcgc cctcatcaag 300
gagctggtgg acctcctggg gctggcgcgc ctcgaggtcc cgggctacga ggcggacgac 360
gtcctggcca gcctggccaa gaaggcggaa aaggagggct acgaggtccg catcctcacc 420
gccgacaaag acctttacca gctcctttcc gaccgcatcc acgccctcca ccccgagggg 480
tacctcatca ccccggcctg gctttgggaa aagtacggcc tgaggcccga ccagtgggcc 540
gactaccggg ccctgaccgg ggacgagtcc gacaaccttc ccggggtcaa gggcatcggg 600
gagaagacgg cgaggaagct tctggaggag tgggggagcc tggaagccct cctcaagaac 660
ctggaccggc tgaagcccgc catccgggag aagatcctgg cccacatgga cgatctgaag 720
ctctcctggg acctggccaa ggtgcgcacc gacctgcccc tggaggtgga cttcgccaaa 780
aggcgggagc ccgaccggga gaggcttagg gcctttctgg agaggcttga gtttggcagc 840
ctcctccacg agttcggcct tctggaaagc cccaaggccc tggaggaggc cccctggccc 900
ccgccggaag gggccttcgt gggctttgtg ctttcccgca aggagcccat gtgggccgat 960
cttctggccc tggccgccgc cagggggggc cgggtccacc gggcccccga gccttataaa 1020
gccctcaggg acctgaagga ggcgcggggg cttctcgcca aagacctgag cgttctggcc 1080
ctgagggaag gccttggcct cccgcccggc gacgacccca tgctcctcgc ctacctcctg 1140
gacccttcca acaccacccc cgagggggtg gcccggcgct acggcgggga gtggacggag 1200
gaggcggggg agcgggccgc cctttccgag aggctcttcg ccaacctgtg ggggaggctt 1260
gagggggagg agaggctcct ttggctttac cgggaggtgg agaggcccct ttccgctgtc 1320
ctggcccaca tggaggccac gggggtgcgc ctggacgtgg cctatctcag ggccttgtcc 1380
ctggaggtgg ccgaggagat cgcccgcctc gaggccgagg tcttccgcct ggccggccac 1440
cccttcaacc tcaactcccg ggaccagctg gaaagggtcc tctttgacga gctagggctt 1500
cccgccatcg gcaagacgga gaagaccggc aagcgctcca ccagcgccgc cgtcctggag 1560
gccctccgcg aggcccaccc catcgtggag aagatcctgc agtaccggga gctcaccaag 1620
ctgaagagca cctacattga ccccttgccg gacctcatcc accccaggac gggccgcctc 1680
cacacccgct tcaaccagac ggccacggcc acgggcaggc taagtagctc cgatcccaac 1740
ctccagaaca tccccgtccg caccccgctt gggcagagga tccgccgggc cttcatcgcc 1800
gaggaggggt ggctattggt ggccctggac tatagccaga tagagctcag ggtgctggcc 1860
cacctctccg gcgacgagaa cctgatccgg gtcttccagg aggggcggga catccacacg 1920
gagaccgcca gctggatgtt cggcgtcccc cgggaggccg tggaccccct gatgcgccgg 1980
gcggccaaga ccatcaactt cggggtcctc tacggcatgt cggcccaccg cctctcccag 2040
gagctagcca tcccttacga ggaggcccag gccttcattg agcgctactt tcagagcttc 2100
cccaaggtgc gggcctggat tgagaagacc ctggaggagg gcaggaggcg ggggtacgtg 2160
gagaccctct tcggccgccg ccgctacgtg ccagacctag aggcccgggt gaagagcgtg 2220
cgggaggcgg ccgagcgcat ggccttcaac atgcccgtcc agggcaccgc cgccgacctc 2280
atgaagctgg ctatggtgaa gctcttcccc aggctggagg aaatgggggc caggatgctc 2340
cttcaggtcc acgacgagct ggtcctcgag gccccaaaag agagggcgga ggccgtggcc 2400
cggctggcca aggaggtcat ggagggggtg tatcccctgg ccgtgcccct ggaggtggag 2460
gtggggatag gggaggactg gctctccgcc aaggag 2496
<210> 4
<211> 2496
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 4
atgaggggga tgctgcccct ctttgagccc aagggccggg tcctcctggt ggacggccac 60
cacctggcct accgcacctt ccacgccctg aagggcctca ccaccagccg gggggagccg 120
gtgcaggcgg tctacggctt cgccaagagc ctcctcaacg ccctcaagga ggacggggac 180
gcggtgatcg tggtctttga cgccaaggcc ccctccttcc gccacgaggc ctacgggggg 240
tacaaggcgg gccgggcccc cacgccggag gactttcccc ggcaactcgc cctcatcaag 300
gagctggtgg acctcctggg gctggcgcgc ctcgaggtcc cgggctacga ggcggacgac 360
gtcctggcca gcctggccaa gaaggcggaa aaggagggct acgaggtccg catcctcacc 420
gccgacaaag acctttacca gctcctttcc gaccgcatcc acgccctcca ccccgagggg 480
tacctcatca ccccggcctg gctttgggaa aagtacggcc tgaggcccga ccagtgggcc 540
gactaccggg ccctgaccgg ggacgagtcc gacaaccttc ccggggtcaa gggcatcggg 600
gagaagacgg cgaggaagct tctggaggag tgggggagcc tggaagccct cctcaagaac 660
ctggaccggc tgaagcccgc catccgggag aagatcctgg cccacatgga cgatctgaag 720
ctctcctggg acctggccaa ggtgcgcacc gacctgcccc tggaggtgga cttcgccaaa 780
aggcgggagc ccgaccggga gaggcttagg gcctttctgg agaggcttga gtttggcagc 840
ctcctccacg agttcggcct tctggaaagc cccaaggccc tggaggaggc cccctggccc 900
ccgccggaag gggccttcgt gggctttgtg ctttcccgca aggagcccat gtgggccgat 960
cttctggccc tggccgccgc cagggggggc cgggtccacc gggcccccga gccttataaa 1020
gccctcaggg acctgaagga ggcgcggggg cttctcgcca aagacctgag cgttctggcc 1080
ctgagggaag accttggcct cccgcccggc gacgacccca tgctcctcgc ctacctcctg 1140
gacccttcca acaccacccc cgagggggtg gcccggcgct acggcgggga gtggacggag 1200
gaggcggggg agcgggccgc cctttccgag aggctcttcg ccaacctgtg ggggaggctt 1260
gagggggagg agaggctcct ttggctttac cgggaggtgg agaggcccct ttccgctgtc 1320
ctggcccaca tggaggccac gggggtgcgc ctggacgtgg cctatctcag ggccttgtcc 1380
ctggaggtgg ccgaggagat cgcccgcctc gaggccgagg tcttccgcct ggccggccac 1440
cccttcaacc tcaactcccg ggaccagctg gaaagggtcc tctttgacga gctagggctt 1500
cccgccatcg gcaagacgga gaagaccggc aagcgctcca ccagcgccgc cgtcctggag 1560
gccctccgcg aggcccaccc catcgtggag aagatcctgc agtaccggga gctcaccaag 1620
ctgaagagca cctacattga ccccttgccg gacctcatcc accccaggac gggccgcctc 1680
cacacccgct tcaaccagac ggccacggcc acgggcaggc taagtagctc cgatcccaac 1740
ctccagaaca tccccgtccg caccccgctt gggcagagga tccgccgggc cttcatcgcc 1800
gaggaggggt ggctattggt ggccctggac tatagccaga tagagctcag ggtgctggcc 1860
cacctctccg gcgacgagaa cctgatccgg gtcttccagg aggggcacga catccacacg 1920
gagaccgcca gctggatgtt cggcgtcccc cgggaggccg tggaccccct gatgcgccgg 1980
gcggccaaga ccatcaactt cggggtcctc tacggcatgt cggcccaccg cctctcccag 2040
gagctagcca tcccttacga ggaggcccag gccttcattg agcgctactt tcagagcttc 2100
cccaaggtgc gggcctggat tgagaagacc ctggaggagg gcaggaggcg ggggtacgtg 2160
gagaccctct tcggccgccg ccgctacgtg ccagacctag aggcccgggt gaagagcgtg 2220
cgggaggcgg ccgagcgcat ggccttcaac atgcccgtcc agggcaccgc cgccgacctc 2280
atgaagctgg ctatggtgaa gctcttcccc aggctggagg aaatgggggc caggatgctc 2340
cttcaggtcc acgacgagct ggtcctcgag gccccaaaag agagggcgga ggccgtggcc 2400
cggctggcca aggaggtcat ggagggggtg tatcccctgg ccgtgcccct ggaggtggag 2460
gtggggatag gggaggactg gctctccgcc aaggag 2496
Claims (10)
1. a kind of Taq DNA polymerase mutant body, which is characterized in that it is the Taq archaeal dna polymerase as shown in SEQ ID NO.1
Amino acid sequence in insertion, replace or lack one or more amino acid, or one or two in SEQ ID NO.1 sequence
A end adds or deletes one or more amino acid, and compared with the Taq archaeal dna polymerase shown in the SEQ ID NO.1, amplification
The amino acid sequence that sensitivity and yield enhance.
2. Taq DNA polymerase mutant body according to claim 1, which is characterized in that the mutant is in SEQ ID
In sequence shown in NO.1, with the amino acid substitution on following one or more amino acid positions, triplet is used in each substitution
Indicate: alphabet-numeric playing-letter, the wherein position of digital representation mutating acid, letter before number is corresponding to be mutated the ammonia being related to
Base acid, the letter after number indicate the amino acid for replacing amino acid before number: K53N, G364D, R636H.
3. Taq DNA polymerase mutant body according to claim 1, which is characterized in that sequence such as SEQ ID NO.2 institute
Show, or the amino acid sequence with Taq DNA polymerase activity with sequence shown in SEQ ID NO.2 with 80% identity；
It is preferred that having 85% identity, more preferably have 90% identity, most preferably, there is 95% identity.
4. encoding the nucleotide sequence of Taq DNA polymerase mutant body of the present invention.
5. nucleotide sequence according to claim 4, which is characterized in that sequence is as shown in SEQ ID NO.4.
6. a kind of recombinant vector comprising nucleotide sequence as claimed in claim 4.
7. the described in any item Taq DNA polymerase mutant bodies of claims 1 to 3 or claim 4 or 5 nucleotide sequences, or
Application of the recombinant vector as claimed in claim 6 in field of biotechnology；Preferably, the application in the field PCR.
8. application according to claim 7, which is characterized in that reaction additives are added in the amplification system of PCR, it is described to add
Agent is added to be selected from one or more of glycerol, trehalose, DMSO or gelatin；Preferably, the addition volume of the additive is every
The 0.5~15% of the reaction system total volume of a amplified reaction is still more preferably 1~5%, most preferably 1~3%.
9. application according to claim 7, which is characterized in that it include KCl in the amplification system of PCR, the amount of KCl is 20~
The each amplified reaction of 60mM, each amplified reaction of preferably 40~60mM, each amplified reaction of most preferably 50mM.
10. application according to claim 7, which is characterized in that multiplex amplification reagent Multi-PCR Mix used in PCR,
Each amplified reaction includes: 1~3U of Taq-Mut, Tris 20~60mM of 20~30mM, KCl, additive 0.5~15%,
MgCl20.1~0.3mM of 0.5~1.5mM, dNTP, pH7.5~7.7；Wherein Taq-Mut refers to Taq described in claim 1
DNA polymerase mutant body；The KCl further preferred 40~60mM, most preferably 50mM used；Additive be selected from glycerol,
One or more of trehalose, DMSO or gelatin；The additive is preferably 1~5%, and most preferably 1~3%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811414588.XA CN109402082A (en) | 2018-11-26 | 2018-11-26 | A kind of Taq DNA polymerase mutant body and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811414588.XA CN109402082A (en) | 2018-11-26 | 2018-11-26 | A kind of Taq DNA polymerase mutant body and its application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109402082A true CN109402082A (en) | 2019-03-01 |
Family
ID=65455505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811414588.XA Pending CN109402082A (en) | 2018-11-26 | 2018-11-26 | A kind of Taq DNA polymerase mutant body and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109402082A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110684752A (en) * | 2019-10-08 | 2020-01-14 | 南京诺唯赞生物科技有限公司 | Mutant Taq DNA polymerase with improved tolerance as well as preparation method and application thereof |
| CN110747183A (en) * | 2019-10-29 | 2020-02-04 | 南京诺唯赞生物科技有限公司 | Taq DNA polymerase mutant and application thereof |
| CN111172129A (en) * | 2019-12-03 | 2020-05-19 | 顶检医学检验(南京)有限公司 | Phi29DNA polymerase mutant for improving thermal stability, amplification uniformity and amplification efficiency and application thereof |
| CN112725301A (en) * | 2021-03-30 | 2021-04-30 | 中国农业科学院生物技术研究所 | Taq DNA polymerase mutant and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998040496A1 (en) * | 1997-03-12 | 1998-09-17 | The Perkin-Elmer Corporation | Dna polymerases having improved labeled nucleotide incorporation properties |
| WO2006037064A3 (en) * | 2004-09-24 | 2009-04-09 | Li Cor Inc | Mutant polymerases for sequencing and genotyping |
| CN102245761A (en) * | 2008-11-03 | 2011-11-16 | 卡帕生物系统 | Modified type A DNA polymerases |
-
2018
- 2018-11-26 CN CN201811414588.XA patent/CN109402082A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998040496A1 (en) * | 1997-03-12 | 1998-09-17 | The Perkin-Elmer Corporation | Dna polymerases having improved labeled nucleotide incorporation properties |
| WO2006037064A3 (en) * | 2004-09-24 | 2009-04-09 | Li Cor Inc | Mutant polymerases for sequencing and genotyping |
| CN102245761A (en) * | 2008-11-03 | 2011-11-16 | 卡帕生物系统 | Modified type A DNA polymerases |
Non-Patent Citations (2)
| Title |
|---|
| GENBANK ACCESSION NO:P19821.1: "GENBANK ACCESSION NO:P19821.1", 《GENBANK DATABASE》 * |
| 刘鼎一: "Taq DNA聚合酶的定点诱变及保真度研究", 《中国优秀硕士学位论文全文数据库 基础科学辑》 * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110684752A (en) * | 2019-10-08 | 2020-01-14 | 南京诺唯赞生物科技有限公司 | Mutant Taq DNA polymerase with improved tolerance as well as preparation method and application thereof |
| CN110684752B (en) * | 2019-10-08 | 2020-09-29 | 南京诺唯赞生物科技股份有限公司 | Mutant Taq DNA polymerase with improved tolerance as well as preparation method and application thereof |
| CN110747183A (en) * | 2019-10-29 | 2020-02-04 | 南京诺唯赞生物科技有限公司 | Taq DNA polymerase mutant and application thereof |
| CN110747183B (en) * | 2019-10-29 | 2020-10-23 | 南京诺唯赞生物科技股份有限公司 | Taq DNA polymerase mutant and application thereof |
| CN112029748A (en) * | 2019-10-29 | 2020-12-04 | 南京诺唯赞生物科技股份有限公司 | Taq DNA polymerase mutant Mut4 and application thereof |
| CN112029748B (en) * | 2019-10-29 | 2021-03-23 | 南京诺唯赞生物科技股份有限公司 | Taq DNA polymerase mutant Mut4 and application thereof |
| CN111172129A (en) * | 2019-12-03 | 2020-05-19 | 顶检医学检验(南京)有限公司 | Phi29DNA polymerase mutant for improving thermal stability, amplification uniformity and amplification efficiency and application thereof |
| CN112725301A (en) * | 2021-03-30 | 2021-04-30 | 中国农业科学院生物技术研究所 | Taq DNA polymerase mutant and application thereof |
| CN112725301B (en) * | 2021-03-30 | 2021-06-25 | 中国农业科学院生物技术研究所 | Taq DNA polymerase mutant and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109402082A (en) | A kind of Taq DNA polymerase mutant body and its application | |
| KR102084186B1 (en) | Method of identifying genome-wide off-target sites of base editors by detecting single strand breaks in genomic DNA | |
| RU2698125C2 (en) | Libraries for next generation sequencing | |
| KR100510619B1 (en) | Modified thermostable dna polymerase | |
| US6316202B1 (en) | Nucleic acids encoding cold sensitive mutant DNA polymerases | |
| CN110684752B (en) | Mutant Taq DNA polymerase with improved tolerance as well as preparation method and application thereof | |
| CN112029748B (en) | Taq DNA polymerase mutant Mut4 and application thereof | |
| CN109486919B (en) | A kind of PCR amplification reagent and its application | |
| CN110218802B (en) | Method for detecting respiratory pathogen nucleic acid | |
| CN110396543A (en) | A kind of tumour associated gene mutation site screening method | |
| KR20180132711A (en) | Marine DNA polymerase | |
| KR101622442B1 (en) | Dna polymerases with increased 3'-mismatch discrimination | |
| KR101778877B1 (en) | Markers for discrimination of Whangkeumbae and Minibae | |
| Bañuls et al. | A phylogenetic analysis by multilocus enzyme electrophoresis and multiprimer random amplified polymorphic DNA fingerprinting of the Leishmania genome project Friedlin reference strain | |
| WO2023216707A1 (en) | Universal preclinical bio-distribution detection kit for nk cell therapy products | |
| Peng et al. | Kamchatka crab duplex-specific nuclease-mediated transcriptome subtraction method for identifying long cDNAs of differentially expressed genes | |
| EP2675896A1 (en) | Dna polymerases with increased 3'-mismatch discrimination | |
| JP2013530694A (en) | DNA polymerase with increased 3 'end mismatch discrimination | |
| CN113388595B (en) | High-efficiency terminal A-added mutant Taq DNA polymerase and encoding DNA thereof | |
| CN110195102A (en) | A kind of beta Thalassemia methods of genotyping | |
| CN110343757A (en) | A kind of short tandem repeat general probe and its design method and application | |
| CN113337488B (en) | Isolated Cas13 protein | |
| KR102286025B1 (en) | Mass spectrometry using dna polymerases with increased mutation specificity | |
| CN114480327B (en) | Taq DNA polymerase mutant | |
| CN114480328B (en) | Taq DNA polymerase mutant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190301 |
|
| RJ01 | Rejection of invention patent application after publication |